-
Mashup Score: 6A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma - 2 month(s) ago
Background:In situ vaccination for the treatment of cancer aims to trigger an immune response locally that propagates systemically. We have shown that local tre
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Source: www.fda.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
The Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma clinical and laboratory/translational research.
Source: lymphoma.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma - 2 month(s) ago
Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cance
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma - 2 month(s) ago
Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cance
Source: www.businesswire.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Bryan (Hennessy) | Leukemia and Lymphoma Society - 2 month(s) ago
My name is Bryan, but most know me by my stage name Hennessy Williams. I was diagnosed with stage 4 non-Hodgkin Burkitt lymphoma (BL) on July 1st, 2005. I was 20 years old. It was the hardest battle I ever faced, I am lucky to be here, I am lucky to be alive. I am alive because I had a tremendous amount of support from my family and friends, not everyone is blessed with this option. This is why I want to get as many donations as I can for The Leukemia & Lymphoma Society (LLS) so that others will get to feel the support that I did. Fighting cancer as a college student was the hardest battle I ever faced. Today, I am completely fearless and I will not back down to any challenge as long as I’m here. Now I am married have 3 kids of my own and I remember where I came from. Leukemia and lymphoma is a battle that many will face will face and LLS is at the forefront of helping them fight. This past summer 18 years after my bout with stage 4 non-Hodgkin Burkitt lymphoma (BL) began I got to
Source: lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5
– A supplementary Biologics License Application (sBLA) is supported by data from the Phase 1/2 EPCORE™ NHL-1 clinical trial in patients with relapsed or refractory (R/R) follicular lymphoma…
Source: news.abbvie.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 12Cellular Therapy Increases Survival in Recurring B-cell Lymphoma - 2 month(s) ago
A two-year follow-up clinical trial found that a personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated high safety and improved overall survival in patients, according to findings published in Blood.
Source: news.feinberg.northwestern.eduCategories: General Medicine News, Onc News and JournalsTweet-
A two-year follow-up clinical trial found that a new personalized CAR T-cell therapy for relapsed / refractory B-cell #lymphoma demonstrated strong safety and improved overall survival in patients according to findings from @ligordon in @BloodJournal. https://t.co/uEaP7YVbN6… https://t.co/huJ0beXqtX https://t.co/fDuLodlNTQ
-
-
Mashup Score: 11
When a lymphoma tumor fractured her vertebra, Bridget Lemoine received a unique treatment at MD Anderson called spine jack augmentation under the care of Saba Javed, M.D.
Source: www.mdanderson.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Previous Treatment | SWOG - 3 month(s) ago
Clinical Trial Summary (S2207) What is the purpose of this clinical trial? This study is for people with certain types of large B-cell lymphoma (LBCL). It will test 2 study drugs for treating lymphoma that came back or did not respond to previous treatment. Researchers will test adding each study drug to a usual…
Source: www.swog.orgCategories: General Medicine News, Onc News and JournalsTweet-
Study S2207 is for people with large B-cell #lymphoma that came back or didn’t respond to previous treatment. It asks if adding either of the drugs tazemetostat or zanubrutinib to usual treatment can help patients. Learn more at https://t.co/RXxA5bRM3x. Or call 1-800-4-CANCER. https://t.co/OIILZ96xMq
-
SCI leader Ron Levy & others found ISV with intratumoral CpG, local low-dose radiation, and systemic ibrutinib safe & effective in #lymphoma. Activation of immune effectors & dampening immune suppressors were vital for favorable outcomes. https://t.co/UYdvTrGBxF @AshAlizadeh https://t.co/QzhSx38MgT